Poynter has partnered with the Risk Less. Do More. campaign to host a webinar, articles to better inform journalists.

The respiratory syncytial virus (RSV) space may have filled up over the past year, but that isn’t deterring Vicebio or its ...

As an expert in providing solutions to assist virology and microbiology research, Creative Diagnostics has announced the launch of its advanced ...

The National Foundation for Infectious Diseases Sept. 25 released a survey showing that less than one in five U.S. adults are ...

Enanta Pharmaceuticals' EDP-323 shows promising Phase 2a trial results, significantly reducing RSV viral load and symptoms ...

A possible cluster of bird flu infections has grown to include eight people, in what may be the first examples of ...

Vicebio has secured $100mn in Series B funding to further develop its vaccines for multiple respiratory infections.

Enanta Pharmaceuticals Announces Positive Topline Results for EDP-323 in a Phase 2a Human Challenge Study of Healthy Adults Infected With RSV ...

Discover Vicebio's molecular clamp technology as it completes a $100 million series B round for its bivalent vaccine against ...

As the 2024-2025 respiratory virus season gets under way, statewide infectious disease experts urge everyone in Oregon to ...

Respiratory syncytial virus (RSV ... Key exclusion criteria were positivity for the human immunodeficiency virus, concurrent influenza virus infection or bacterial pneumonia, and known or ...

Health officials in North Dakota are encouraging state residents to prepare for the upcoming respiratory illness season.